Recently, a PARP inhibitor called veliparib (ABT-888) has been found to be effective in increasing radio-sensitivity both in cells and xenograft models of HPV+ HNSCC (69, 75). The gene discussed is PARP1; the disease is head and neck squamous cell carcinoma.